- Investing Ideas
- Chinese Pharmaceuticals & Biotech Undervalued based on future growth
Chinese Pharmaceuticals & Biotech Undervalued based on future growth
Results
4
Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)
4 companies
Nanjing King-Friend Biochemical PharmaceuticalLtd
Market Cap: CN¥15.2b
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.
603707
CN¥9.69
7D
-2.1%
1Y
-25.9%
Pacific Shuanglin Bio-pharmacy
Market Cap: CN¥13.2b
Engages in research, development, production, and sales of blood products in China and internationally.
000403
CN¥14.03
7D
-0.6%
1Y
-12.4%
Jiangsu Sinopep-Allsino Biopharmaceutical
Market Cap: CN¥10.3b
A biomedical company, engages in the research and development, production, and sale of peptides, oligonucleotides, and small molecule drugs in China.
688076
CN¥33.72
7D
3.9%
1Y
-12.8%
KPC PharmaceuticalsInc
Market Cap: CN¥9.0b
A pharmaceutical company, engages in the research and development, production, marketing, and commercial wholesale of botanical drugs and natural drugs in the People’s Republic of China and internationally.
600422
CN¥12.04
7D
-2.0%
1Y
-30.2%